Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandy Srinivas

Showing results (91-100 of 153) with videos related to

Pageof 16
Sort By:
European Urology|July 20, 2017
Recommendations for the Management of Rare Kidney CancersRachel H Giles, Toni K Choueiri, Daniel Y Heng, et al.
The Lancet. Oncology|June 11, 2022
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)Neeraj Agarwal, Bradley McGregor, Benjamin L Maughan, et al.
The Lancet. Oncology|August 11, 2012
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based studyLauren C Harshman, Wanling Xie, Georg A Bjarnason, et al.
Clinical Genitourinary Cancer|February 4, 2014
A population-based overview of sequences of targeted therapy in metastatic renal cell carcinomaNimira Alimohamed, Jae-Lyn Lee, Sandy Srinivas, et al.
Circulation|June 28, 2022
Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced MyocarditisHan Zhu, Francisco X Galdos, Daniel Lee, et al.
JAMA Oncology|August 26, 2021
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical TrialSumanta K Pal, Paul H Frankel, Amir Mortazavi, et al.
Clinical Genitourinary Cancer|November 22, 2017
Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient PopulationAndrea Necchi, Gregory R Pond, Sumanta K Pal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2021
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 StudySumanta K Pal, Bradley McGregor, Cristina Suárez, et al.
European Urology|August 22, 2013
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapyRana R McKay, Nils Kroeger, Wanling Xie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial CarcinomaJonathan Rosenberg, Srikala S Sridhar, Jingsong Zhang, et al.
Pageof 16

Showing results (91-100 of 153) with videos related to

Sort By:
Pageof 16
European Urology|July 20, 2017
Recommendations for the Management of Rare Kidney CancersRachel H Giles, Toni K Choueiri, Daniel Y Heng, et al.
The Lancet. Oncology|June 11, 2022
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)Neeraj Agarwal, Bradley McGregor, Benjamin L Maughan, et al.
The Lancet. Oncology|August 11, 2012
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based studyLauren C Harshman, Wanling Xie, Georg A Bjarnason, et al.
Clinical Genitourinary Cancer|February 4, 2014
A population-based overview of sequences of targeted therapy in metastatic renal cell carcinomaNimira Alimohamed, Jae-Lyn Lee, Sandy Srinivas, et al.
Circulation|June 28, 2022
Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced MyocarditisHan Zhu, Francisco X Galdos, Daniel Lee, et al.
JAMA Oncology|August 26, 2021
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical TrialSumanta K Pal, Paul H Frankel, Amir Mortazavi, et al.
Clinical Genitourinary Cancer|November 22, 2017
Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient PopulationAndrea Necchi, Gregory R Pond, Sumanta K Pal, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 7, 2021
Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 StudySumanta K Pal, Bradley McGregor, Cristina Suárez, et al.
European Urology|August 22, 2013
Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapyRana R McKay, Nils Kroeger, Wanling Xie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2020
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial CarcinomaJonathan Rosenberg, Srikala S Sridhar, Jingsong Zhang, et al.
Pageof 16